Abstract
To determine the anti-inflammatory effect and safety of hydroxychloroquine after acute myocardial infarction. In this multicenter, double-blind, placebo-controlled OXI trial, 125 myocardial infarction patients were randomized at a median of 43 h after hospitalization to receive hydroxychloroquine 300 mg (n = 64) or placebo (n = 61) once daily for 6 months and, followed for an average of 32 months. Laboratory values were measured at baseline, 1, 6, and 12 months. The levels of interleukin-6 (IL-6) were comparable at baseline between study groups (p = 0.18). At six months, the IL-6 levels were lower in the hydroxychloroquine group (p = 0.042, between groups), and in the on-treatment analysis, the difference at this time point was even more pronounced (p = 0.019, respectively). The high-sensitivity C-reactive protein levels did not differ significantly between study groups at any time points. Eleven patients in the hydroxychloroquine group and four in the placebo group had adverse events leading to interruption or withdrawal of study medication, none of which was serious (p = 0.10, between groups). In patients with myocardial infarction, hydroxychloroquine reduced IL-6 levels significantly more than did placebo without causing any...Continue Reading
References
Jan 12, 2001·Japanese Circulation Journal·T ObayashiF Marumo
Jul 24, 2001·JAMA : the Journal of the American Medical Association·A D PradhanP M Ridker
Jan 26, 2005·European Journal of Internal Medicine·Amon S GabrielStaffan Ahnve
Jan 19, 2006·Rheumatology·C-H JangD-M Jue
Mar 15, 2011·The Journal of Immunology : Official Journal of the American Association of Immunologists·Alenka KuznikRoman Jerala
Mar 17, 2012·Lancet·UNKNOWN Interleukin-6 Receptor Mendelian Randomisation Analysis (IL6R MR) ConsortiumJuan Pablo Casas
Jul 26, 2012·Internal Medicine Journal·C TangM Nikpour
Sep 26, 2013·European Heart Journal. Acute Cardiovascular Care·Emer JoyceNiall Mahon
Jan 6, 2016·Journal of the American Heart Association·Tarun S SharmaAndroniki Bili
May 11, 2016·European Heart Journal·Ola KlevelandLars Gullestad
Aug 29, 2017·The New England Journal of Medicine·Paul M RidkerUNKNOWN CANTOS Trial Group
Apr 20, 2018·Mediators of Inflammation·Alberto FlorisAlberto Cauli
Jun 3, 2018·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Clotilde ChatreYves-Marie Pers
Aug 31, 2018·European Heart Journal·Kristian ThygesenUNKNOWN ESC Scientific Document Group
Nov 13, 2018·The New England Journal of Medicine·Paul M RidkerUNKNOWN CIRT Investigators
Nov 17, 2019·The New England Journal of Medicine·Jean-Claude TardifFrançois Roubille
Sep 17, 2020·JAMA Cardiology·Nicholas J MercuroHoward S Gold
Apr 17, 2021·Journal of the American College of Cardiology·Kaspar BrochLars Gullestad